Difference between revisions of "Zi-Ming Zhao"
From Chuang Lab
| Line 1: | Line 1: | ||
| − | == | + | == Zi-Ming Zhao, Ph.D.== |
---- | ---- | ||
| Line 18: | Line 18: | ||
[https://twitter.com/Dr_ZiMingZhao twitter@Dr_ZiMingZhao] | [https://twitter.com/Dr_ZiMingZhao twitter@Dr_ZiMingZhao] | ||
| − | [[https://www.jax.org/research-and-faculty/research- | + | [[https://www.jax.org/research-and-faculty/faculty/research-scientists/zi-ming-zhao VISIT ME AT JAX]] |
===ABOUT ZI-MING ZHAO, Ph.D.=== | ===ABOUT ZI-MING ZHAO, Ph.D.=== | ||
I have been interested in understanding genetic origins and molecular evolution of life and human diseases, and finding cures for various human diseases particularly cancer and infectious diseases. My current focus is studying cancer clinical genomics from the perspectives of molecular evolution and population genetics. My goal is to understand the process of tumorigenesis, metastasis and drug resistance, and to identify markers for cancer diagnosis, prognosis, and therapeutics. | I have been interested in understanding genetic origins and molecular evolution of life and human diseases, and finding cures for various human diseases particularly cancer and infectious diseases. My current focus is studying cancer clinical genomics from the perspectives of molecular evolution and population genetics. My goal is to understand the process of tumorigenesis, metastasis and drug resistance, and to identify markers for cancer diagnosis, prognosis, and therapeutics. | ||
| + | |||
| + | ===SELECTED PUBLICATIONS=== | ||
| + | [https://bmcclinpathol.biomedcentral.com/articles/10.1186/s12907-018-0070-7 '''Zhao ZM''', Wang J, Ugwuowo UC, Wang L, and Townsend JP. Primary hepatic neuroendocrine carcinoma: report of two cases. '''''BMC Clinical Pathology'''''. 2018.] | ||
| + | |||
| + | [https://www.nature.com/articles/s41388-017-0105-z Cannataro VL, Gaffney SG, Stender C, '''Zhao ZM''', Philips M, Greenstein AE, Townsend JP. Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C. '''''Oncogene'''''. 2018] | ||
| + | |||
| + | [https://academic.oup.com/mbe/article-abstract/34/11/3006/4055061?redirectedFrom=fulltext '''Zhao ZM''', Campbell MC, Li N, Lee DSW, Zhang Z, Townsend JP, Detection of regional variation in selection intensity within protein-coding genes using DNA sequence polymorphism and divergence, '''''Molecular Biology and Evolution'''''. 2017] | ||
| + | |||
| + | [https://www.ncbi.nlm.nih.gov/pubmed/26858460 '''Zhao ZM''', Zhao B, Bai Y, Iamarino A, Gaffney SG, Schlessinger J, Lifton RP, Rimm DL, Townsend JP. Early and multiple origins of metastatic lineages within primary tumors. '''''Proc Natl Acad Sci U S A'''''. 2016 Feb 23;113(8):2140-5.] | ||
| + | |||
| + | [https://www.ncbi.nlm.nih.gov/pubmed/27687306 Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, '''Zhao ZM''', Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. '''''Ann Oncol'''''. 2016 Sep 29. pii: mdw436.] | ||
| + | |||
| + | |||
| + | [[https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/48067188/?sort=date&direction=ascending <font color=blue>VIEW FULL LIST OF PUBLICATIONS</font>]] | ||
Latest revision as of 10:41, 4 June 2018
Contents
Zi-Ming Zhao, Ph.D.
Research Scientist
Understands molecular mechanisms of tumorigenesis and drug resistance using cancer clinical genomic data.
[Bioinformatics],[Cancer], [Computational Biology], [Genetics And Genomics], [Infectious Disease Research].
Contact me:
Ziming.Zhao@jax.org
860-837-2130
ABOUT ZI-MING ZHAO, Ph.D.
I have been interested in understanding genetic origins and molecular evolution of life and human diseases, and finding cures for various human diseases particularly cancer and infectious diseases. My current focus is studying cancer clinical genomics from the perspectives of molecular evolution and population genetics. My goal is to understand the process of tumorigenesis, metastasis and drug resistance, and to identify markers for cancer diagnosis, prognosis, and therapeutics.
